摘要
目的:构建针对SARS相关冠状病毒M蛋白基因的重组核酸疫苗,观察其免疫小鼠后肌体的抗体产生情况, 探讨其作为抗SARS病毒疫苗的可能性。方法:通过分子生物学的方法构建SARS相关冠状病毒M蛋白基因真核表达质粒 pcDNA3．1/M,经肌注免疫健康BALB/c小鼠,在免疫后的2、4、6周取小鼠血清,用ELISA法检测其中的抗体。结果:接种含M 基因的真核表达质粒pcDNA3．1/M的低剂量组和高剂量组的小鼠血清在接种2周后就可检测出SARS-CoV特异性IgG,第4 周时,这种特异性IgG水平有升高趋势,第6周时,血清中的抗体含量与4周时无大的差异。高剂量组产生抗体与低剂量组产生抗体无显著差异。pcDNA3．1空载体接种的对照组未检测出特异性抗体(其OD值低于0．18)。结论:构建的真核表达质粒 pcDNA3．1/M能诱导小鼠产生了针对SARS的抗体。
Objective：To construct recombinant DNA vaccine containing SARS-CoV M gene and to observe the production of SARS-CoV specific antibodies in mice. Methods： A recombinant plasmid-pcDNA3, l/hi was constructed by molecular biology technique. The mice was immtmized with the recombinant DNA vaccine. After 2,4,6 week,the SARS-CoV antibodies in the sera of mice were detected with ELISA kit. Results： After 2 weeks, SARS-CoV specific antibodies were detected in mice. There were an ascended trend in antibodies concentration at 4 weeks. And simultanity, SARS-CoV specific antibodies was not detected in mice injected with vacancy carrier. There were not remarkable difference in mice injected with high and low quantity plasmid. Conclusion： A recombinant plasmid pcDNA3.1/M could induce SARS-CoV specific antibodies in mice.
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2006年第1期20-22,28,共4页
Chinese Journal of Immunology
基金
四川大学SARS专项基金项目
